News

October 14, 2021

POINT Biopharma joins Tri-party Collaboration to Advance Ga-68 Imaging Products

ARTMS has entered into a tri-party co-operation with fellow industry leaders, POINT Biopharma and the Canadian Molecular Imaging Probe Consortium (CanProbe), a joint venture between the Centre for Probe Development...

September 28, 2021

POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models. Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022

September 23, 2021

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria, Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21.

September 15, 2021

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive mCRPC

Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa

September 8, 2021

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Northstar Medical Radioisotopes and POINT Biopharma today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).